Acer Therapeutics Inc. (ACER) News
Filter ACER News Items
ACER News Results
|Loading, please wait...|
ACER News Highlights
- For ACER, its 30 day story count is now at 2.
- Over the past 6 days, the trend for ACER's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- APTX are the most mentioned tickers in articles about ACER.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference. Conference:11th Annual LifeSci Part
Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and 
Acer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of 
Phase 2a trial initiation expected in Q1 2022
No summary available.
Equities analysts expect that Acer Therapeutics Inc. (NASDAQ:ACER) will announce earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Acer Therapeutics earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Acer Therapeutics posted earnings of ($0.50) per share during the same 
Vanguard Group Inc. grew its stake in shares of Acer Therapeutics Inc. (NASDAQ:ACER) by 6.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 179,143 shares of the biopharmaceutical companys stock after acquiring an additional 11,094 shares during the period.  The post Vanguard Group Inc. Boosts Stock Holdings in Acer Therapeutics Inc. (NASDAQ:ACER) appeared first on ETF Daily News .
Some of the stocks that may grab investor focus today are: Wall Street expects Agilent Technologies, Inc. (NYSE: A) to report quarterly earnings at $1.03 per share on revenue of $1.45 billion before the opening bell. Agilent shares rose 0.4% to $164.90 in after-hours trading. NIO Inc. (NYSE: NIO) shares dropped more than 9% in the week ending Nov. 19, underperforming most of its electric-vehicle peers. The stock, however, saw an upward bounce in late trading on Friday as the company announced Fr